Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy

Clinical and Experimental Immunology

Volumn 118, Issue 1, 1999, Pages 78-86

  Imami, Nesrina ^a,b   Hardy, G A D ^a   Nelson, M R ^b   Morris Jones, S ^b   Al Shahi, R ^b   Antonopoulos, C ^a   Gazzard, B ^b   Gotch, F M ^a  

^a Department of Immunology ^*  (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti retroviral therapy; Cytokines; HIV 1; Immune reconstitution; T cell responses

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; VIRUS INDUCTION; VIRUS LOAD;

EID: 0032859377     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01012.x     Document Type: Article

References (35)

1. 1 Gill J, Moyle G, Nelson M. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 count following highly active anti-retroviral therapy (HAART). AIDS 1998; 12:680.
2. 2 Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351:228-30.
3. 3 Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-5.
4. 4 Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256-61.
5. 5 Paxton WA, Martin SR, Tse Det al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Med 1996; 2:412-7.
6. 6 Clerici M, Shearer GM. A TH1 - TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107-11.
7. 7 Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15:575-81.
8. 8 Clerici M, Wynn TA, Berzofsky JA, Blatt SP, Hendrix CW, Sher A, Coffman RL, Shearer GM. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with human immunodeficiency virus. J Clin Invest 1994; 93:768-75.
9. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
10. - T cells. AIDS 1994; 8:431-41.
11. +CD28 T cell expansion - anergy or activation? Clin Exp Immunol 1996; 104:180-4.
12. 12 Rosenberg YJ, Anderson AO. Pabst R. HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? Immunol Today 1998; 19:10-17.
13. 13 Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ntonavir. J Infect Dis 1996; 173:321-9.
14. 14 Schnittman SM, Fox L. Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases. AIDS Res Hum Retrovir 1997; 13:815-8.
15. +1 T-cell repertoire that are not immediately restored by antiretroviral or immune-based therapies. Nature Med 1997; 3:533-40.
16. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
17. 17 Bidwell J. Advances in DNA-based HLA-typing methods. Immunol Today 1994; 15:303-7.
18. 18 Bunce M, O'Neill CM, Barnardo MCNM, Krausa P, Browning MJ, Morris PJ, Welsh KI. Phototyping: comprehensive DNA typing for HLA-A,B,C, DRB1,DRB3,DRB4,DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46:355-67.
19. 10 Imami N, Larché M, Ritter MA. Inhibition of alloreactivity by mAb MR6: differential effects on IL-2-and IL-4-producing human T cells. Int Immunol 1994; 6:1575-84.
20. + memory T cells. J Exp Med 1997; 186:859-65.
21. 21 Kovacs JA, Vogel S, Albert JMet al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6.
22. 22 Davey RT Jr, Chaitt DG, Piscitelli SC et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type I-infected persons. J Infect Dis 1997; 175:781-9.
23. + cytotoxic cells. Proc Natl Acad Sci USA 1994; 91:4185-9.
24. 24 Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373:438-41.
25. + T cell turnover. Science 1996; 274:1543-7.
26. 26 Funaro A, Spagnoli GC, Ausiello CM, Alessio M, Roggero S, Delia D, Zaccolo M, Malavasi F. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol 1990; 145:2390-6.
27. 27 Bonnefoy J-Y, Plater-Zyberk C, Lecoanet-Henchoz S, Gauchat J-F, Aubry J-P, Graber P. A new role for CD23 in inflammation. Immunol Today 1996; 17:418-20.
28. 28 Katira A, Knox KA, Finney M, Michell RH, Wakelman M, Gordon J. Inhibition by glucocortcoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40. Clin Exp Immunol 1993; 92:347-52.
29. 29 Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-58.
30. 30 Akbar AN, Terry L, Timms A, Beverly PCL, Janossy G. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 1988; 140:2171-8.
31. 1 subjects. J Clin Invest 1997; 100:2737-43.
32. 32 Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177:483-92.
33. 33 Farace F, Angevin E, Dietrich PY, Leboullaire C, Vanderplancke J, Escudier B, Triebel F. Low-dose IL-2 treatment: activation of discrete T-and NK-cell sub-populations in vivo. Int J Cancer 1995; 62:523-8.
34. 34 Baldwin GC. The biology of granulocyte-macrophage colony-stimulating factor: effects on hematopoietic and nonhematopoietic cells. Dev Biol 1992; 151:352-67.
35. 35 Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. J Immunol 1997; 158:3947-58.